ATXI — AVENUE THERAPEUTICS, INC.

—
OTC · Health Care · Pharmaceuticals · CIK 1644963 ·
Last close
$0.28
Market Cap
$922.6K
52W High
$0.96
52W Low
$0.15
ADV30
1,172
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -704,000 -691,000 1,530,000 1,520,000 1,605,000
Jun 2026 0 — -707,000 -690,000 1,976,000 1,942,000 1,407,000
Mar 2026 0 — -714,000 -695,000 2,468,000 2,417,000 1,270,000
Dec 2025 0 — -955,000 -709,000 2,931,000 2,855,000 1,099,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,384,000
Investing CF
—
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.52
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-106,874,000
Inventory
—
Receivables
$800,000
ST Investments
—
EBIT TTM
$-3,100,000
Pretax Income TTM
$-2,803,000
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
—
Free Cash Flow
$-631,500
Enterprise Value
$35,062
Total Cash
$1,942,000
Total Debt
$0
Shares Out
3,294,967
Trailing EPS
$-0.85
Book Value
$0.57
ROE
-164.8%
ROA
-63.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,404,000 -3,286,000 -2,909,000 2,931,000 1,099,000 1,832,000 -1,833,000
Dec 2024 0 -11,283,000 -11,652,000 2,672,000 816,000 2,797,000 -9,026,000
Dec 2023 0 -14,540,000 -10,377,000 1,850,000 1,196,000 1,582,000 -9,451,000
Dec 2022 0 -8,043,000 -3,552,000 6,845,000 3,579,000 3,905,000 -7,596,000

TTM Snapshot

Revenues TTM
$-14,000
NetIncome TTM
$-2,777,000
OpCashFlow TTM
—
Assets (Latest)
$1,976,000
Forward EPS
$-3.14

Peers — same industry

TickerNameMarket CapLastDaily %
OGEN ORAGENICS INC $947.5K $0.21 —
SKVI SKINVISIBLE, INC. $972.7K $0.18 —
APVO Aptevo Therapeutics Inc. $834.5K $0.46 —
PTIX Protagenic Therapeutics, Inc.\new $814.6K $0.45 —
GOVX GeoVax Labs, Inc. $1.09M $2.01 —

News headlines (Yahoo Finance, 1h cache)

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
2026-02-23 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.